TheraLead™
Predictive/Personalized Medicine (Blood-based assay)
CommercialActive
Key Facts
Indication
Predictive/Personalized Medicine (Blood-based assay)
Phase
Commercial
Status
Active
Company
About GenoSensor Corporation
Founded in 2015, GenoSensor Corporation has established itself as a provider of genomic technologies and bioassay services, leveraging integrated high-throughput laboratory and microarray fabrication facilities. The company's portfolio includes research tools like microRNA arrays and qPCR kits, as well as diagnostic products, most notably its GS™ COVID-19 RT-PCR Kit which received FDA Emergency Use Authorization. While its core business supports life science research, GenoSensor also markets a blood-based molecular assay, TheraLead™, for clinical applications via a partner, Clinicogen, indicating a move towards predictive and personalized medicine.
View full company profile